A Review of Hematopoietic Cell Transplantation in Australia and New Zealand, 2005 to 2013

• Published in: Biology of blood and marrow transplantation Vol. 22; no. 2; pp. 284 - 291
• Main Authors: Nivison-Smith, Ian, Bardy, Peter, Dodds, Anthony J, Ma, David D.F, Aarons, Donna, Tran, Steven, Wilcox, Leonie, Szer, Jeff
• Format: Journal Article
• Language: English
• Published: United States Elsevier Inc 01.02.2016
• Subjects: Adolescent; Adult; Aged; Australia; Child; Child, Preschool; Hematology, Oncology and Palliative Medicine; Hematopoietic cell transplantation; Hematopoietic Stem Cell Transplantation - methods; Hematopoietic Stem Cell Transplantation - mortality; History, 21st Century; Humans; Infant; Middle Aged; New Zealand; Transplantation Conditioning - methods; Transplantation Conditioning - mortality; Young Adult; New Zealand; Australia; Hematopoietic cell transplantation
• ISSN: 1083-8791; 1523-6536
• DOI: 10.1016/j.bbmt.2015.09.009

Abstract This report describes hematopoietic cell transplantation (HCT) activity and outcome in Australia and New Zealand during the years 2005 to 2013. In 2013, 1018 autologous, 221 allogeneic with related donors, and 264 allogeneic with unrelated donors HCT were performed in 40 centers in Australia, with corresponding figures of 147, 39, and 47 in 6 centers in New Zealand. Annual numbers of HCT in 2013 increased, compared to 2005, by 25% in Australia and by 52% in New Zealand. The majority of both allogeneic and autologous HCT used peripheral blood as the stem cell source for all years studied. Major indications for transplantation were acute myeloid leukemia (AML), acute lymphoblastic leukemia (ALL), plasma cell disorders, and non-Hodgkin lymphoma (NHL). Overall survival probabilities at 5 years after transplantation for adult (16+) allogeneic first HCT recipients were 54.2% for ALL, 46.0% for AML, 48.4% for myelodysplastic syndromes, and 58.6% for NHL. Consistent patterns over time include a steady increase in HCT, particularly for older recipients, relatively constant numbers of allografts using cord blood, and a recent increase in the number of allografts with 2 or more HLA-mismatched related donors.